Arcutis Biotherapeutics, Inc. ARQT ZORYVE foam — Product revenue, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s zoryve foam — product revenue, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s ZORYVE foam — product revenue, net?
- Arcutis Biotherapeutics, Inc. (ARQT) reported ZORYVE foam — product revenue, net of $49.63M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s ZORYVE foam — product revenue, net changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s ZORYVE foam — product revenue, net increased by 64.1% year-over-year, from $30.24M to $49.63M.
- What does ZORYVE foam — product revenue, net mean?
- This metric represents the total net sales generated from a specific pharmaceutical product formulation after accounting for returns, discounts, and rebates. It serves as a primary indicator of market adoption, commercial traction, and the successful transition from clinical development to commercialization for a key dermatological therapeutic. Tracking this revenue stream helps investors evaluate the product's growth trajectory and its contribution to the company's overall top-line performance.